AGYT.F Stock Overview
A commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Allergy Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.052 |
| 52 Week High | UK£0.06 |
| 52 Week Low | UK£0.02 |
| Beta | 1.35 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -89.80% |
| 5 Year Change | n/a |
| Change since IPO | -97.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| AGYT.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 2.0% |
| 1Y | n/a | 13.7% | 32.4% |
Return vs Industry: Insufficient data to determine how AGYT.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AGYT.F performed against the US Market.
Price Volatility
| AGYT.F volatility | |
|---|---|
| AGYT.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AGYT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AGYT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 612 | Manuel Llobet | www.allergytherapeutics.com |
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.
Allergy Therapeutics plc Fundamentals Summary
| AGYT.F fundamental statistics | |
|---|---|
| Market cap | US$299.68m |
| Earnings (TTM) | -US$50.46m |
| Revenue (TTM) | US$69.27m |
4.3x
P/S Ratio-5.9x
P/E RatioIs AGYT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGYT.F income statement (TTM) | |
|---|---|
| Revenue | UK£55.20m |
| Cost of Revenue | UK£25.46m |
| Gross Profit | UK£29.74m |
| Other Expenses | UK£69.95m |
| Earnings | -UK£40.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0084 |
| Gross Margin | 53.87% |
| Net Profit Margin | -72.86% |
| Debt/Equity Ratio | 622.8% |
How did AGYT.F perform over the long term?
See historical performance and comparison